# Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

> **NCT06614140** · PHASE1,PHASE2 · COMPLETED · sponsor: **Seqker Biosciences, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Cancer
- Solid Tumor, Adult

## Interventions

- **BIOLOGICAL:** Personalized Neoantigen Peptide Vaccine with Poly-ICLC and Checkpoint Inhibitors

## Key facts

- **NCT ID:** NCT06614140
- **Lead sponsor:** Seqker Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-24
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06614140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06614140, "Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06614140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*